Does tesamorelin's FDA approval apply to this?

No. It is approved for reducing visceral fat in HIV-associated lipodystrophy, at a stated dose, on its own. A blend containing it at an unstated ratio alongside an unapproved peptide is not the thing that was approved.

Which split should I look for?

We do not recommend one. What matters is knowing which you have: 5/5, 10/5 and 10/3 all exist, and a dose in units written for one is wrong for the other two.

Muscle & performanceWeight loss

Tesamorelin / Ipamorelin

Tesa ipa · Tesa/Ipa blend · tesamorelin with ipamorelin

PreclinicalProhibited in sportReviewed 25 Aug 2026

What is in the vial

The same name covers more than one vial. Pick the one you have — a dose in units written for one of these is wrong for the other.

10 mg vial — 5 mg of each
Compound	Per vial	Share	Bought separately
TesamorelinGHRH analogue, and the only component here approved for anything in humans.	5 mg	50%	$26–$28
IpamorelinGhrelin receptor agonist. Triggers a pulse without the appetite and cortisol effects of older secretagogues.	5 mg	50%	$17–$20
Total	10 mg		$44–$49

The even split, and the most commonly listed.

The ratio is fixed in the vial: choosing a dose of one component chooses the dose of all the others. The separate-vials column is the cheapest confirmed listing to the median across vendors, for the masses this vial holds. We do not price blend vials themselves — hold it against whatever you are being quoted.

Tesamorelin is the one component in any of these blends with an approval behind it: the FDA cleared it for HIV-associated lipodystrophy, where it reduces visceral fat. Ipamorelin has no approval anywhere.

The blend is sold at several splits — 5 mg of each, 10 mg tesamorelin with 5 mg ipamorelin, and 10 mg with 3 mg. Unlike CJC/Ipa, where the larger vial keeps the ratio, these are genuinely different formulations and a protocol written for one is wrong for the others.

Its approval is for a specific population and a specific outcome. It is not evidence that this blend does anything in anybody else, and no trial has tested the combination.

How it works

Two mechanisms arriving together, not studied as a mixture.

Tesamorelin is a stabilised GHRH analogue, shown in trials to reduce visceral adipose tissue in HIV-associated lipodystrophy.

Ipamorelin is a selective ghrelin receptor agonist and initiates a growth hormone pulse.

As with CJC/Ipa the receptors differ, so the stated rationale is additive rather than competing release.

Quick reference

Commonly described dose: 300 mcg–500 mcg
How often: Once daily before bed, 5 days a week
Route: Subcutaneous
Where: Abdomen, Thigh
Timing: Commonly before bed and away from food. Not established for the mixture.
Storage once mixed: Refrigerated, 30 days

These describe what sources report, not what you should do. Full detail and provenance in the dosing section below.

Price index

Per-milligram pricing across vendors arrives with the directory. We are recording prices now so the history exists when the page ships.

Vocabulary on this page

Unit: A mark printed on an insulin syringe. A unit is not a fixed volume. What it represents depends entirely on the syringe's scale.
GHRH analogue: A synthetic version of the hormone that tells the pituitary to release growth hormone. One of the two receptor routes into a growth hormone pulse.
Blend: One vial containing several peptides at a fixed ratio, reconstituted and drawn together.
Vial: The small sealed glass container a peptide is sold in, holding a stated mass of freeze-dried powder under a rubber stopper.
Injection site: Where on the body an injection is given. Rotating between sites is standard practice for anything given repeatedly.
Peptide: A short chain of amino acids: the same building blocks as a protein, in a chain short enough to behave differently.

The whole glossary →

Regulatory status — United States

Tesamorelin is approved by the FDA for HIV-associated lipodystrophy. Ipamorelin is approved nowhere, and the mixture is approved nowhere. Sold as a research chemical at several ratios.

Last reviewed 25 Aug 2026. Regulatory positions in this category change frequently; we date this line so you can see how current it is.

What it is studied for

Each entry states the evidence behind it. We do not rank indications by effectiveness — for most compounds here, that would be a claim nobody can support.

Raising growth hormone and reducing visceral fat

Published review

What the blend is sold for.

EvidenceTesamorelin has trial evidence for visceral fat in HIV-associated lipodystrophy specifically. Ipamorelin has none. The mixture has not been studied.

Identity and clearance

Molecule

Class: Pre-mixed blend of two growth hormone secretagogues

Sold at 1:1, 2:1 and roughly 3:1 tesamorelin to ipamorelin. The name does not identify the ratio.

Dose protocols reported in sources

Displayed for reference only. Every row says where it came from, and a trial protocol and a community convention are not the same kind of information. None of this is fed into the calculator, and none of it is a recommendation.

Dose protocols reported in sources, with the source of each.
Goal	Dose	Frequency	Route	Units, 10 mg vial	Source	Start this protocol
Commonly described community protocol	300 mcg – 500 mcg	Once daily before bed, 5 days a week	SubcutaneousTotal blend. The split varies by vial, so the same volume delivers different amounts of each component depending on which you hold.	15–25 u	Community practice	Start this

Start this copies a row into a protocol of your own, which you can then edit. Where a source gave a dose range or an ambiguous frequency, those fields arrive empty — we will not pick a number on your behalf.

CheckRows marked community practice describe what people commonly do, drawn from public discussion. They are not derived from any trial and are not evidence that a dose is safe or effective.

Calculator

Work out what to draw

Pre-filled with a 10 mg vial as a worked example. These are not recommended values — change them to match the vial in front of you.

Draw to 6 units on a 1 mL U-100 syringe. That is 0.06 mL, containing 300 mcg of Tesamorelin / Ipamorelin.

Concentration5mg / mL

Volume drawn0.06mL

Doses per vial33.3doses

Per unit50mcg / unit

6 units sits exactly on a printed line.

Get a shareable image Read the profile

Bioalmanac performs arithmetic on values you enter. It does not recommend doses, schedules or compounds, and nothing here is medical advice. Confirm every calculation against your vial and syringe before drawing, and speak with a licensed healthcare provider.

Open this calculation in the full calculator

Units, concentration, bacteriostatic water — the glossary defines the vocabulary, and a unit is not a fixed volume.

Safety

Reported effects

Everything from two compounds at oncePublished review
Unknown
No human study of the mixture. Each component's own adverse-effect profile applies, and they cannot be separated if something goes wrong.
Injection site reactionsCommunity practice
Commonly reported
Injection site rednessApproved label
Reported in tesamorelin trials
The most common adverse effect in the approved indication.
Joint pain and fluid retentionApproved label
Reported in tesamorelin trials

When to stop

Any allergic response: rash, hives, facial swelling or difficulty breathing. Seek urgent care.
Persistent numbness or tingling in the hands.
New or worsening joint swelling.

Interactions and situations that need care

Active or previous cancerAvoid
Raising growth hormone and IGF-1 is a proliferative signal. Tesamorelin's own labelling carries a malignancy contraindication.
Diabetes or impaired glucose toleranceUse caution
Growth hormone opposes insulin. Tesamorelin trials recorded worsened glucose control.
Wanting to control the dose of one componentUse caution
Two compounds at a fixed ratio means Two doses chosen at once. Running them separately is the only way to dose them separately.
Pregnancy and breastfeedingAvoid
No safety data for any component, let alone the mixture.
Competing in a tested sportAvoid
Components are WADA S2, prohibited at all times.

SportProhibited by the World Anti-Doping Agency under S2: Peptide Hormones, Growth Factors, Related Substances, at all times, in and out of competition. Growth hormone secretagogues are named explicitly in S2.

What to expect

HonestlyThere is no human efficacy data for this compound, so there is no evidence-based timeline to give. Any site publishing a week-by-week schedule of expected effects has invented it.

Tesamorelin's approval is for HIV-associated lipodystrophy, not for general fat loss and not for this blend.
Three different splits are sold under one name. This is the blend where reading the vial matters most.
The mixture has not been studied. Ipamorelin has no approval anywhere.
Fixed ratio: you cannot raise the tesamorelin without raising the ipamorelin.

Storage and handling

Freeze-dried powder: Refrigerated at 2–8 °C, protected from light.
After mixing: Refrigerated at 2–8 °C and used within about 30 days. A blend cannot be split. A contaminated vial takes every component with it.
Long-term, frozen: Unopened powder is stable at −20 °C or colder.

Printable one-pager How to reconstitute a vial, step by step

With other peptides

Tesamorelin / CJC-1295 / Ipamorelincaution
That blend contains both of these plus CJC-1295. Running both means taking tesamorelin and ipamorelin twice.
CJC-1295 / Ipamorelincaution
Both contain ipamorelin, and both raise growth hormone through a GHRH analogue. Running them together doubles the ipamorelin.

Check this against a whole stack

Checking your vial

Research chemicals carry no manufacturing standard, so what the vial looks like is often the only quality signal available before you use it. More on assessing quality and COAs.

Clear and colourless after reconstitution
Nothing here is coloured. A tinted solution is not this blend.
Cloudiness or visible particles
Discard it.
No stated split
Three ratios circulate under this name. Without the split, no dose can be calculated for either component.

Questions

Does tesamorelin's FDA approval apply to this?: No. It is approved for reducing visceral fat in HIV-associated lipodystrophy, at a stated dose, on its own. A blend containing it at an unstated ratio alongside an unapproved peptide is not the thing that was approved.
Which split should I look for?: We do not recommend one. What matters is knowing which you have: 5/5, 10/5 and 10/3 all exist, and a dose in units written for one is wrong for the other two.

References

Component evidence for common peptide blends: an assessment of what is known separately
Preclinical peptide literature, 2024 · Assessment of the separate component literatures
Cell culture and rodent models
Every component of the common blends is supported by animal or cell-culture work only. No study has examined any of these combinations as a mixture, so combination evidence is weaker than the single-compound evidence. That is itself preclinical.
Community and vendor practice, unverified
Vendor listings and community protocols, 2026 · Anecdote
Self-selected, unverified
Ratios and doses as vendors sell and users describe them. Ratios vary between sellers, so a blend bought from two vendors is not necessarily the same product.

Related compounds

Tesamorelin / CJC-1295 / Ipamorelin

Three growth hormone secretagogues in one vial, commonly 6:3:3. Two of the three do the same job, which is the thing worth knowing before buying it.

CJC-1295 / Ipamorelin

The default growth hormone blend: a GHRH analogue with a ghrelin agonist, usually 5 mg of each. Two mechanisms that genuinely differ, unlike the triple.

Semaglutide

A long-acting GLP-1 receptor agonist approved for type 2 diabetes and for weight management, dosed once weekly.

Tirzepatide

A once-weekly dual agonist that activates both the GIP and GLP-1 receptors, approved for type 2 diabetes and for weight management.

Keep this page honest

If something here is wrong, out of date, or missing a source, tell us and we will fix it and say that we did.

Suggest a correction

This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice. No clinician reviews these pages.

Page last updated 25 Aug 2026